The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Member discount codes
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / Antibody therapeutics product data

Antibody therapeutics product data

The Antibody Society continuously collects data for approved antibody therapeutics and those in regulatory review. A searchable table of this data is below. Products that were granted approvals but subsequently withdrawn from the market are included in the table. Biosimilar products are excluded.

Format, Fc modification and cell expression system data were compiled by Drs.Alicia Chenoweth and Silvia Crescioli, King’s College London, who also built the data table below.

Please cite our data as follows:
The Antibody Society. Therapeutic monoclonal antibodies approved or in regulatory review. (date accessed); www.antibodysociety.org/antibody-therapeutics-product-data

International Non-Proprietary NameBrand NameTargetFormatSpecificitySequence sourceBackboneLight ChainConjugated / uncognugatedLinkerPayloadPayload Mechanism of ActionFc ModificationsReason for Fc ModificationsTherapeutic AreaIndication First Approved or ReviewedFirst EU approval yearFirst US approval yearFirst global approval (country, year) or country in review Expression system 
ZimberelimabPD-1Full-length antibodyMonospecificHumanIgG4lambdaUnconjugatedS228PHinge stabilisationOncologyClassical Hodgkin’s lymphomaNANAChina, 2021To be confirmed
VedolizumabEntyvioα4β7 integrinFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedL235A, G237Remove Fc effector functionsImmunologyUlcerative colitis, Crohn disease 20142014US, 2014Chinese hamster ovary (CHO) cells
UstekinumabStelaraIL-12/23Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-ImmunologyPsoriasis20092009EU, 2009Murine myeloma cells (Sp2/0)
UblituximabBRIUMVICD20Full-length antibodyMonospecificChimerichIgG1kappaUnconjugatedLow fucoseImprove FcγRIIIa binding/Improve ADCCImmunologyMultiple sclerosisEU review2022YB2/0 cells
TremelimumabImjudoCTLA-4Full-length antibodyMonospecificHumanIgG2kappaUnconjugatedNone-OncologyAntineoplastic; liver cancerPos. opinion2022US, 2022Murine myeloma non-secreting 0 (NS0) cells
Trastuzumab duocarmazine(Pending)HER2Full-length antibodyMonospecificHumanizedIgG1kappaADCcleavable linker-drug (vc-seco-DUBA)DuocarmycinDNA minor-groove-binding alkylationNone-CancerBreast cancerEU reviewIn reviewTo be confirmed
TrastuzumabHerceptinHER2Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-OncologyBreast cancer20001998US, 1998Chinese hamster ovary (CHO) cells
TralokinumabAdtralzaIL-13Full-length antibodyMonospecificHumanhIgG4lambdaUnconjugatedNone-ImmunologyAtopic dermatitis20212021EU, 2021Mouse myeloma cells
Tositumomab-I131BexxarCD20Full-length antibodyMonospecificMurinemIgG2alambdaRadio-immunotherapeuticIodine-131I-131 produces beta and gamma emissionsNone-OncologyNon-Hodgkin LymphomaNA2003#US, 2003Murine hybridoma
ToripalimabTuoyiPD-1Full-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedS228PHinge stabilisingOncologyNasopharyngeal carcinomaEU reviewIn reviewTo be confirmed
TocilizumabRoActemra, ActemraIL-6RFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-ImmunologyRheumatoid arthritis20092010Japan, 2005Chinese hamster ovary (CHO) cells
Tixagevimab, cilgavimab EvusheldSARS-CoV-2Full-length antibodies, mixture of 2MonospecificHumanIgG1kappaUnconjugatedL234F L235E M252Y S254T T256E P331S Reduce Fc effector function (L234F L235E P331S) and extend half-life ( M252Y S254T T256E)
Infectious diseasesCOVID-192022EUA grantedEU, 2022Chinese hamster ovary (CHO) cells
Tisotumab vedotin, tisotumab vedotin-tftvTIVDAKTissue factorFull-length antibodyMonospecificHumanhIgG1kappaADCCleavable mc-val-cit-PABC type linkerMonomethyl Auristatin E (MMAE)tubulin polymerization inhibitorNone-OncologyCervical cancerNA2021US, 2021Chinese hamster ovary (CHO) cells
Tislelizumab(Pending)PD-1Full-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedS228P; E233P, F234V, L235A, D265AHinge stabilising; Abrogate FcγRs bindingOncologyEsophageal squamous cell carcinoma EU reviewIn reviewTo be confirmed
Tildrakizumab (tildrakizumab-asmn)IlumyaIL-23 p19Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-ImmunologyPlaque psoriasis20182018US, 2018Chinese hamster ovary (CHO) cells
TezepelumabTezspireThymic stromal lymphopoietinFull-length antibodyMonospecificHumanhIgG2lambdaUnconjugatedNone-ImmunologySevere asthma20222021US, 2021Chinese hamster ovary (CHO) cells
Teprotumumab (teprotumumab-trbw)TepezzaIGF-1RFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-OphthalmologyThyroid eye diseaseNA2020US, 2020Chinese hamster ovary (CHO) cells
TeplizumabTZIELDCD3Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedL234A; L235ARemove Fc effector functionsImmunologyType 1 diabetesNA2022US, 2022To be confirmed
TeclistamabTECVAYLIBCMA, CD3Full-length antibodyBispecificHumanizedIgG4; Hetero H, HL exchangedlambdaUnconjugatedHetero HH: F405L-R409K x WT (R409); both chains: S228P and F234A, L235AHinge-stabilising (S228P) and Fc-silencing (F234A, L235A)OncologyMultiple myeloma20222022EU, 2022Chinese hamster ovary (CHO) cells
TebentafuspKIMMTRAKgp100, CD3TCR-scFv fusion proteinBispecificHumanizedhscFV fused with a TCRTo be confirmedFusion proteinNone-OncologyMetastatic uveal melanoma20222022US, 2022E. coli bacteria
Talquetamab(Pending)G protein-coupled receptor 5D, CD3Full-length antibodyBispecificHumanizedIgG4lambda/kappaUnconjugatedHetero HH: F405L-R409K x WT; both chains: S228P, F234A-L235AHinge-stabilization (S228P), Reduce Fc effector function (F234A-L235A)CancerMultiple myelomaNAIn reviewTo be confirmed
Tagitanlimab(Pending)PD-L1Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedL234A L235A G237AReduce Fc effector functionOncologyNasopharyngeal carcinoma, solid tumor NANARegulatory review in ChinaTo be confirmed
Tafolecimab(Pending)PCSK9Full-length antibodyMonospecificHumanIgG2kappaUnconjugatedNone-OtherPrimary hypercholesterolemia (including heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia) and mixed dyslipidemiaNANARegulatory review in ChinaTo be confirmed
Tafasitamab
(tafasitamab-cxix)
Monjuvi, MinjuviCD19Full-length antibodyMonospecificHumanizedhIgG1/2 hybridkappaUnconjugatedS239D; I332EImprove FcγRIIIa binding/Improve ADCCOncologyDiffuse large B-cell lymphoma20212020US, 2020Chinese hamster ovary (CHO) cells
Sutimlimab, sutimlimab-jomeEnjaymoC1sFull-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedS228P; L235EHinge stabilising; remove Fc effector functionsImmunologyCold agglutinin disease20222022US, 2022Chinese hamster ovary (CHO) cells
SugemalimabCejemly®PD-L1Full-length antibodyMonospecificHumanIgG4lambdaUnconjugatedS228PHinge stabilisationOncologyNon-small cell lung cancerNANAChina, 2021To be confirmed
SpesolimabSPEVIGO®IL-36 receptorFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedL234A/L235ARemove Fc effector functionsImmunologyGeneralized pustular psoriasis 20222022US, 2022Chinese hamster ovary (CHO) cells
SotrovimabXevudySARS-CoV-2Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedM428L /N434S Extends half-lifeInfectious diseasesCOVID-192021NAAustralia, 2021Chinese hamster ovary (CHO) cells
Socazolimab(Pending)PD-L1Full-length antibodyMonospecificHumanIgG1lambda2UnconjugatedNone-OncologyCervical cancerNANARegulatory review in ChinaTo be confirmed
SintilimabTyvytPD-1Full-length antibodyMonospecificHumanhIgG4kappaUnconjugatedS228PHinge stabilisingOncologyNon-small cell lung cancerNAIn reviewTo be confirmed
SiltuximabSylvantIL-6Full-length antibodyMonospecificChimeric mouse/humanhIgG1kappaUnconjugatedNone-ImmunologyCastleman disease20142014US, 2014Chinese hamster ovary (CHO) cells
SerplulimabHANSIZHUANGPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationOncologyMicrosatellite instability-high solid tumorsNANAChina, 2022To be confirmed
SecukinumabCosentyxIL-17aFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-ImmunologyPsoriasis20152015Japan, 2014Chinese hamster ovary (CHO) cells
Satralizumab (satralizumab-mwge)EnspryngIL-6RFull-length antibodyMonospecificHumanizedhIgG2kappaUnconjugatedNone-ImmunologyNeuromyelitis optica spectrum disorder20212020Canada, 2020Chinese hamster ovary (CHO) cells
SarilumabKevzaraIL-6RFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-ImmunologyRheumatoid arthritis20172017Canada, 2017Chinese hamster ovary (CHO) cells
Sacituzumab govitecan (sacituzumab govitecan-hziy)TRODELVYTROP-2Full-length antibodyMonospecificHumanizedhIgG1kappaADCpH-sensitive cleavable linkerSN38topoisomerase I inhibitorNone-OncologyTriple-neg. breast cancer20212020US, 2020Murine myeloma cells
Rozanolixizumab(Pending)FcRnFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge-stabilization ImmunologyGeneralized myasthenia gravisEU reviewIn reviewTo be confirmed
Romosozumab (romosozumab-aqqg)EvenitySclerostinFull-length antibodyMonospecificHumanizedhIgG2kappaUnconjugatedNone-Musculoskeletal DisordersOsteoporosis in postmenopausal women at increased risk of fracture20192019Japan, 2019Chinese hamster ovary (CHO) cells
RituximabMabThera, Rituxan CD20Full-length antibodyMonospecificChimeric mouse/humanhIgG1kappaUnconjugatedNone-OncologyNon-Hodgkin lymphoma19981997US, 1997Chinese hamster ovary (CHO) cells
Risankizumab (risankizumab-rzaa)SkyriziIL-23 p19Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedL234A; L235ARemove Fc effector functionsImmunologyPlaque psoriasis20192019Japan, 2019Chinese hamster ovary (CHO) cells
RipertamabAnpingxiCD20Full-length antibodyMonospecificChimericIgG1kappaUnconjugatedNone-OncologyNon-Hodgkin's lymphomaNANAChina, 2022To be confirmed
Retifanlimab(Pending)PD-1Full-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedS228PHinge stabilisingOncologyCarcinoma of the anal canalMAA withdrawnIn review (2nd cycle)To be confirmed
ReslizumabCinqaero, CinqairIL-5Full-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedNone-ImmunologyAsthma20162016US, 2016Murine myeloma non-secreting 0 (NS0) cells
RelatlimabOpdualag (relatlimab + nivolumab combo)LAG-3Full-length antibodyMonospecificHumanhIgG4kappaUnconjugatedS228PHinge stabilisingOncologyMelanoma20222022US, 2022Chinese hamster ovary (CHO) cells
RegdanvimabRegkironaSARS-CoV-2Full-length antibodyMonospecificHumanhIgG1lambdaUnconjugatedNone-Infectious diseasesCOVID-192021NARepublic of Korea, 2021Chinese hamster ovary (CHO)-K1 cells
Raxibacumab(Pending)B. anthrasis PAFull-length antibodyMonospecificHumanhIgG1lambdaUnconjugatedNone-Infectious DiseasesAnthrax infectionNA2012US, 2012Murine myeloma non-secreting 0 (NS0) cells
Ravulizumab (ravulizumab-cwvz)UltomirisC5Full-length antibodyMonospecificHumanizedhIgG2(CH1-hinge)/hIgG4(CH2-CH3)kappaUnconjugatedM428L; N434SIncrease half-lifeHematological DisordersParoxysmal nocturnal hemoglobinuria20192018US, 2018Chinese hamster ovary (CHO) cells
RanibizumabLucentisVEGFFabMonospecificHumanizedhIgG1 FabkappaUnconjugatedNot applicable
-OphthalmologyMacular degeneration20072006US, 2006E. coli bacteria
RamucirumabCyramzaVEGFR2Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-OncologyGastric cancer20142014US, 2014Murine myeloma non-secreting 0 (NS0) cells
RacotumomabVaxira®GM3Full-length antibodyMonospecificMurineIgG1kappa--OncologyNon-small cell lung cancerNANACuba, 2013
PucotenlimabPuyouhengPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228P, S254T, V308P, N434A Hinge stabilsation, half-life extensionCancerMetastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors, NANAChina, 2022To be confirmed
ProlgolimabFortecaPD-1Full-length antibodyMonospecificHumanIgG1V-lambda C-kappaUnconjugatedL234A/L235AReduce Fc effector functionOncologyMelanomaNANARussia, 2020To be confirmed
Polatuzumab vedotin (polatuzumab vedotin-piiq)PolivyCD79bFull-length antibodyMonospecificHumanizedhIgG1kappaADCProtease-cleavable Valine-Citrulline (mc-val-cit PABC linkerMonomethyl Auristatin E (MMAE)tubulin polimerization inhibitorNone-OncologyDiffuse large B-cell lymphoma20202019US, 2019Chinese hamster ovary (CHO) cells
PertuzumabPerjetaHER2Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-OncologyBreast Cancer20132012US, 2012Chinese hamster ovary (CHO) cells
Penpulimab(Pending)PD-1Full-length antibodyMonospecificHumanizedhIgG1To be confirmedUnconjugatedL234A L235A G237A Reduce Fc effector functionsOncologyMetastatic nasopharyngeal carcinomaNAIn reviewTo be confirmed
PembrolizumabKeytrudaPD1Full-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedS228PHinge stabilisingOncologyMelanoma20152014US, 2014Chinese hamster ovary (CHO) cells
PanitumumabVectibixEGFRFull-length antibodyMonospecificHumanhIgG2kappaUnconjugatedNone-OncologyColorectal cancer20072006US, 2006Chinese hamster ovary (CHO) cells
PalivizumabSynagisRSVFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-Infectious DiseasesPrevention of respiratory syncytial virus infection19991998US, 1998Murine myeloma non-secreting 0 (NS0) cells
Pabinafusp alfaIZCARGOTransferrin receptorFull-length antibodyMonospecificHumanizedIgG1kappaImmunoconjugateIduronate-2-sulfataseNone-Metabolic disordersMucopolysaccharidosis type IINANAJapan, 2021To be confirmed
OzoralizumabNanozoraⓇ TNF, albuminNanobodyBispecificHumanizedUnconjugatedNone-ImmunologyRheumatoid arthritisNANAJapan, 2022To be confirmed
Ormutivimab(Pending)Rabies virus surface glycoprotein 4Full-length antibodyMonospecificHumanIgG1lambda2UnconjugatedNone-Infectious diseasePost-exposure prophylaxis of rabiesNANAChina, 2022Chinese hamster ovary (CHO)-K1 cells
Omburtamab(Pending)B7-H3 (CD276)Full-length antibodyMonospecificMurinehIgG1kappaRadiolabeledIodine-131I-131 produces beta and gamma emissionsNone-OncologyCentral nervous system/leptomeningeal metastasis from neuroblastomaNeg. opinionIn review (2nd cycle)To be confirmed
OmalizumabXolairIgEFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-ImmunologyAsthma20052003US, 2003Chinese hamster ovary (CHO) cells
OlokizumabARTLEGIAIL-6Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationImmunologyRheumatoid arthritisNANARussia, 2020To be confirmed
OlaratumabLartruvoPDGFRαFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-OncologySoft tissue sarcoma2016#2016US, 2016Murine myeloma non-secreting 0 (NS0) cells
OfatumumabArzerraCD20Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-OncologyChronic lymphocytic leukemia2010#2009US, 2009Murine myeloma non-secreting 0 (NS0) cells
OcrelizumabOCREVUSCD20Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-ImmunologyMultiple sclerosis20182017US, 2017Chinese hamster ovary (CHO) cells
ObinutuzumabGazyva, Gazyvaro CD20Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedLow-fucoseImprove FcγRIIIa binding/Improve ADCCOncologyChronic lymphocytic leukemia20142013US, 2013Chinese hamster ovary (CHO) cells, Coexpression with GnT III and α-ManII in CHO cells (GlycoMAb Technology)
ObiltoxaximabAnthimB. anthrasis PAFull-length antibodyMonospecificChimeric mouse/humanhIgG1kappaUnconjugatedNone-Infectious DiseasesPrevention of inhalational anthrax20202016US, 2016Murine GS-NS0 myeloma cells
NivolumabOpdivoPD1Full-length antibodyMonospecificHumanhIgG4kappaUnconjugatedS228PHinge stabilisingOncologyMelanoma, non-small cell lung cancer 20152014US, 2014Chinese hamster ovary (CHO) cells
NirsevimabBeyfortusRSVFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedM252Y, S254T, T256EExtends half-lifeInfectious diseasesRespiratory syncytial virus infection2022In reviewEU, 2022Chinese hamster ovary (CHO) cells
NimotuzumabTheraCIM, BIOMAB-EGFREGFRFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-OncologyHead and neck cancerNANACuba, 2002To be confirmed
NetakimabEfleiraIL-17Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedM252Y/S254T/T256EHalf-life extensionImmunologyPlaque psoriasisNANARussia, 2019To be confirmed
NemolizumabMitchgaIL-31 receptor alphaFull-length antibodyMonospecificHumanizedIgG2kappaUnconjugatedC222S and H268QStructure stability, possibly reduce Fc effector functionImmunologyPruritus with atopic dermatitisNANAJapan, 2022To be confirmed
NecitumumabPortrazzaEGFRFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-OncologyNon-small cell lung cancer20152015US, 2015Murine myeloma non-secreting 0 (NS0) cells
NebacumabCentoxinEndotoxinFull-length antibodyMonospecificHumanhIgMkappaUnconjugatedNone-Infectious DiseasesGram-negative sepsis1991*#NANetherlands, England, France, Germany, 1991Heteromyeloma cell line A6(H4C5)
Naxitamab-gqgkDANYELZAGD2Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-OncologyHigh-risk neuroblastoma and refractory osteomedullary diseaseNA2020US, 2020Chinese hamster ovary (CHO) cells
NatalizumabTysabria4 integrinFull-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedNone-ImmunologyMultiple sclerosis20062004US, 2004Murine myeloma non-secreting 0 (NS0) cells
Narsoplimab(Pending)MASP-2Full-length antibodyMonospecificHumanhIgG4lambdaUnconjugatedS228PHinge stabilisingHematological DisordersHematopoietic stem cell transplant-associated thrombotic microangiopathiesNAIn reviewTo be confirmed
Narlumosbart(Pending)RANK-LFull-length antibodyMonospecificHumanIgG4UnconjugatedS228PHinge stabilisationMusculoskeletal DisordersGiant cell tumor of boneNANARegulatory review in ChinaChinese hamster ovary (CHO) cells, cell line CHO-S,
glycoform alfa
Muromonab-CD3Orthoclone Okt3CD3Full-length antibodyMonospecificMurinemIgG2akappaUnconjugatedNone-ImmunologyReversal of kidney transplant rejection1986*1986#US, 1986Murine hybridoma
Moxetumomab pasudotox (moxetumomab pasudotox-tdfk)LumoxitiCD22dsFv immunotoxinMonospecificMurinemIgG1 dsFv fused with PE38 exotoxinImmunotoxinPE38Not applicable
-OncologyHairy cell leukemia20212018US, 2018 [to be withdrawn in July 2023]E. coli bacteria
MosunetuzumabLunsumioCD20, CD3Full-length antibodyBispecificHumanizedIgG1; Hetero H, HL assemblykappaUnconjugatedHetero HH: T366W x T366S-L368A-Y407V (KiH); N297G (Fc-aglycosylated)Improve FcγRIIIa binding/Improve ADCCOncologyFollicular lymphoma20222022EU, 2022Chinese hamster ovary (CHO) cells
Mogamulizumab (mogamulizumab-kpkc)PoteligeoCCR4Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedAfucosylatedImprove FcγRIIIa binding/Improve ADCCOncologyMycosis fungoides or Sézary syndrome20182018Japan, 2012Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology)
Mirvetuximab soravtansineELAHEREFolate receptor alphaFull-length antibodyMonospecificHumanizedIgG1kappaADCcleavable sulfo-SPDB linkerDM4Tubulin polymerization inhibitorNone-OncologyOvarian cancerNA2022US, 2022Chinese hamster ovary (CHO) cells
Mirikizumab(Pending)IL-23p19Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228P; F234A, L235A Hinge stabilisation; Reduce Fc effector functionImmunologyUlcerative colitisEU reviewIn reviewTo be confirmed
MepolizumabNucalaIL-5Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-ImmunologySevere eosinophilic asthma20152015US, 2015Chinese hamster ovary (CHO) cells
Margetuximab-cmkbMARGENZAHER2Full-length antibodyMonospecificChimeric mouse/humanhIgG1kappaUnconjugatedF243L; R292P; Y300L; V305I; P396LImprove FcγRIIIa binding/Improve ADCC and decrease affinity for human inhibitory FcγRIIB (CD32B)OncologyHER2+ metastatic breast cancerNA2020US, 2020Chinese hamster ovary (CHO) cells
Loncastuximab tesirineZynlontaCD19Full-length antibodyMonospecificHumanizedhIgG1/kkappaADCProtease-cleavable Valine-Citrulline linkerpyrrolobenzodiazepines (PBD) dimer SG3199DNA minor-groove bindingNone-OncologyDiffuse large B-cell lymphoma20222021US, 2021Chinese hamster ovary (CHO) cells
LevilimabIlsiraIL-6 receptorFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedE233P/L234V/L235A and M252Y/S254T/T256EReduce Fc effector function and extend half-lifeImmunologyInflammation due to COVID-19 infectionNANARussia, 2020To be confirmed
LecanemabLeqembiAmyloid beta protofibrilsFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-Neurological disordersAlzheimer's diseaseEU review2023To be confirmed
Lebrikizumab(Pending)IL-13Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge-stabilizationImmunologyAtopic dermatitisEU reviewNATo be confirmed
Lanadelumab (lanadelumab-flyo)TakhzyroPlasma kallikrelinFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-Genetic DiseasesHereditary angioedema attacks20182018US, 2018Chinese hamster ovary (CHO) cells
IxekizumabTaltzIL-17aFull-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedS228PHinge stabilisingImmunologyPsoriasis20162016US, 2016Chinese hamster ovary (CHO) cells
ItolizumabAlzumabCD6Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-ImmunologyPsoriasisNANAIndia, 2013To be confirmed
Isatuximab (isatuximab-irfc)SarclisaCD38Full-length antibodyMonospecificChimeric mouse/humanhIgG1kappaUnconjugatedNone-OncologyMultiple myeloma20202020US, 2020Chinese hamster ovary (CHO) cells
IpilimumabYervoyCTLA-4Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-OncologyMetastatic melanoma20112011US, 2011Chinese hamster ovary (CHO) cells
Inotuzumab ozogamicinBESPONSACD22Full-length antibodyMonospecificHumanizedhIgG4kappaADCAcid-labile hydrozone linkerCalicheamicinDNA-binding and double breaks inductionS228PHinge stabilisingOncologyAcute lymphoblastic leukemia20172017US, 2017Chinese hamster ovary (CHO) cells
InfliximabRemicadeTNFFull-length antibodyMonospecificChimeric mouse/humanhIgG1kappaUnconjugatedNone-ImmunologyCrohn disease19991998US, 1998Murine myeloma cells (Sp2/0)
InetetamabCipterbinHER2Full-length antibodyMonospecificHumanizedIgG1UnconjugatedEnhanced ADCC/ADCP (exact mutations not found)OncologyHER2-positive metastatic breast cancerNANAChina, 2020To be confirmed
Inebilizumab (inebilizumab-cdon)UpliznaCD19Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedAfucosylatedImprove FcγRIIIa binding/Improve ADCCImmunologyNeuromyelitis optica spectrum disorders20222020US, 2020Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology)
IdarucizumabPraxbindDabigatranFabMonospecificHumanizedhIgG1 FabkappaUnconjugatedNot applicable
-Hematological DisordersReversal of dabigatran-induced anticoagulation20152015US, 2015Chinese hamster ovary (CHO) cells
Ibritumomab tiuxetanZevalinCD20Full-length antibodyMonospecificMurinemIgG1kappaRadio-immunotherapeuticchalating agent MX-DTPAYttrium-90Y-90 produces beta emissionsNone-OncologyNon-Hodgkin lymphoma20042002US, 2002Chinese hamster ovary (CHO) cells
Ibalizumab (ibalizumab-uiyk)TrogarzoCD4Full-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedNone-Infectious DiseasesHIV infection20192018US, 2018Murine myeloma non-secreting 0 (NS0) cells
GuselkumabTREMFYAIL-23 p19Full-length antibodyMonospecificHumanhIgG1lambdaUnconjugatedNone-ImmunologyPlaque psoriasis20172017US, 2017Chinese hamster ovary (CHO) cells
GolimumabSimponiTNFFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-ImmunologyRheumatoid and psoriatic arthritis, ankylosing spondylitis 20092009US, 2009Murine myeloma cells (Sp2/0)
Glofitamab(Pending)CD20, CD3eCrossMab; Fab-Fc(G1) x Fab-Fab-FcBispecificIgG1lambda/kappaUnconjugatedHetero HH: S354C-T366W x Y349C-T366S-L368A-Y407V (KiH and extra cysteines); HL-pairing: CrossMab; both chains: L234A, L235A, P329G (Fc-silencing)Chain pairing, Reduce Fc effector functionOncologyDiffuse large B-cell lymphoma EU reviewIn reviewTo be confirmed
Geptanolimab (Genolimzumab)(Pending)PD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationOncologyPeripheral T cell lymphomaNANARegulatory review in ChinaTo be confirmed
Gemtuzumab ozogamicinMylotargCD33Full-length antibodyMonospecificHumanizedhIgG4kappaADCAcid-labile hydrozone linkerCalicheamicinDNA-binding and double breaks inductionS228PHinge stabilisingOncologyAcute myeloid leukemia20182017; 2000#US, 2000Murine myeloma non-secreting 0 (NS0) cells
Galcanezumab (galcanezumab-gnlm)EmgalityCGRPFull-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedS228P; F234A; L235ARemove Fc effector functionsNeurological disordersMigraine prevention20182018US, 2018Chinese hamster ovary (CHO) cells
Fremanezumab (fremanezumab-vfrm)AjovyCGRPFull-length antibodyMonospecificHumanizedhIgG2ΔakappaUnconjugatedA330S; P331SRemove Fc effector functionsNeurological disordersMigraine prevention20192018US, 2018Chinese hamster ovary (CHO) cells
Faricimab, faricimab-svoaVabysmoVEGF-A, Ang-2Full-length antibodyBispecificHumanized/humanhIgG1kappa/lambdaUnconjugatedL234A; L235A; P329G; I253A; H310A; H435A; S354C + T366W (in heavy chain A); Y349C + T366S + L368A + Y407V (in heavy chain B)Remove Fc effector functions; Reduce half-life; CrossMab "knob-in-hole" mutations for bispecific generation Ophthalmology Neovascular age-related macular degeneration, diabetic macular edema20222022US, 2022Chinese hamster ovary (CHO) cells
EvolocumabRepathaPCSK9Full-length antibodyMonospecificHumanhIgG2lambdaUnconjugatedNone-OtherHigh cholesterol20152015EU, 2015Chinese hamster ovary (CHO) cells
EvinacumabEvkeezaAngiopoietin-like 3Full-length antibodyMonospecificHumanhIgG4kappaUnconjugatedS228PHinge stabilisingGenetic DiseasesHomozygous familial hypercholesterolemia20212021US, 2021Chinese hamster ovary (CHO) cells
Erenumab (erenumab-aooe)AimovigCGRP receptorFull-length antibodyMonospecificHumanhIgG2lambdaUnconjugatedNone-Neurological disordersMigraine prevention20182018US, 2018Chinese hamster ovary (CHO) cells
Eptinezumab (eptinezumab-jjmr)VYEPTICGRPFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedAglycosylated (N297A)Remove Fc effector functionsNeurological disordersMigraine prevention20222020US, 2020Pichia pastoris yeast cells
Epcoritamab(Pending)CD20, CD3Full-length antibodyBispecificHumanizedIgG1; Hetero Hlambda/kappaUnconjugatedHetero HH, HL exchanged: L234F x K409R (bispecific assembly) both chains L234F, L235E, D265A (Fc silencing)Chain pairing, Reduce Fc effector functionCancerDiffuse large B-cell lymphomaEU reviewIn reviewTo be confirmed
EnvafolimabENWEIDAPD-L1Single domain antibody-FcMonospecificHumanized single doman; human FcIgG1UnconjugatedC220S/D265A/P331SReduce Fc effector function (ADCC/ADCP)OncologyMicrosatellite instability-high or deficient MisMatch Repair advanced solid tumorsNANAChina, 2021To be confirmed
Enfortumab vedotin (enfortumab vedotin-ejfv)PadcevNectin-4Full-length antibodyMonospecificHumanhIgG1kappaADCProtease-cleavable Valine-Citrulline (mc-val-cit PABC linkerMonomethyl Auristatin E (MMAE)tubulin polymerization inhibitorNone-OncologyUrothelial cancer20222019US, 2019Chinese hamster ovary (CHO) cells
EmicizumabHemlibraFactor Ixa, XFull-length antibodyBispecificHumanizedhIgG4kappaUnconjugatedS228P; K196Q; F296Y; E356K; K439E; L445P; G446 > del; K447 > delHinge stabilising, asymmetric electrostatic steering mutations for bispecific creationHematological DisordersHemophilia A20182017US, 2017Chinese hamster ovary (CHO) cells
Emapalumab (emapalumab-lzsg)GamifantIFNgFull-length antibodyMonospecificHumanhIgG1lambdaUnconjugatedNone-OncologyPrimary hemophagocytic lymphohistiocytosisNA2018US, 2018Chinese hamster ovary (CHO) cells
ElotuzumabEmplicitiSLAMF7Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-OncologyMultiple myeloma20162015US, 2015Murine myeloma non-secreting 0 (NS0) cells
EfalizumabRaptivaCD11aFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-ImmunologyPsoriasis2004#2003#US, 2003Chinese hamster ovary (CHO) cells
EdrecolomabPanorexEpCAMFull-length antibodyMonospecificMurinemIgG2akappaUnconjugatedNone-OncologyColon cancer1995*#NAGermany, 1995
EculizumabSolirisC5Full-length antibodyMonospecificHumanizedhIgG2(CH1-hinge)/hIgG4(CH2-CH3)kappaUnconjugatedNone-Hematological DisordersParoxysmal nocturnal hemoglobinuria20072007US, 2007Murine myeloma non-secreting 0 (NS0) cells
DurvalumabIMFINZIPD-L1Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedL234F; L235E; P331SRemove Fc effector functionsOncologyBladder cancer20182017US, 2017Chinese hamster ovary (CHO) cells
DupilumabDupixentIL-4R αFull-length antibodyMonospecificHumanhIgG4kappaUnconjugatedS228PHinge stabilisingImmunologyAtopic dermatitis20172017US, 2017Chinese hamster ovary (CHO) cells
DostarlimabJemerliPD-1Full-length antibodyMonospecificHumanizedhIgG4kappaUnconjugatedS228PHinge stabilisingOncologyEndometrial cancer20212021EU, 2021Chinese hamster ovary (CHO) cells
Donanemab(Pending)Amyloid beta, N3pG (N-terminal truncated) Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-Neurological disordersAlzheimer's diseaseNAIn reviewTo be confirmed
Docaravimab and MiromavimabTwinrabRabies virusFull-length antibodyTwo monospecific antibodiesMurineIgG2b and IgG1kappaUnconjugatedNone-Infectious diseaseRabies exposureNANAIndia, 2019To be confirmed
Disitamab vedotinAidixiHER2Full-length antibodyMonospecificHumanizedIgG1kappaADCcleavable maleimidocaproyl-valyl-citrullinyl-p-amiobenzyloxycarbonyl (mc-val-cit-PABC) type linkerMMAENone-OncologyGastric cancerNANAChina, 2021To be confirmed
DinutuximabUnituxinGD2Full-length antibodyMonospecificChimeric mouse/humanhIgG1kappaUnconjugatedNone-OncologyNeuroblastoma2017; 2015#2015US, 2015Murine myeloma cells (Sp2/0)
DenosumabProliaRANK-LFull-length antibodyMonospecificHumanhIgG2kappaUnconjugatedNone-Musculoskeletal DisordersBone Loss20102010EU, 2010Chinese hamster ovary (CHO) cells
DaratumumabDarzalexCD38Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-OncologyMultiple myeloma20162015US, 2015Chinese hamster ovary (CHO) cells
DaclizumabZinbryta; ZenapaxCD25Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-ImmunologyMultiple sclerosis#; prevention of kidney transplant rejection#2016#; 1999#2016#; 1997#US, 1997Murine myeloma non-secreting 0 (NS0) cells
Crovalimab(Pending)Complement C5Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedL235R, G236R, S239K, A327G, A330S, P331S; M428L, N434A, Q438R, S440E Impair Fc binding/effector functions; increase FcnR binding without increasing RF bindingHematological DisordersAtypical hemolytic uremic syndromeNANARegulatory review in ChinaTo be confirmed
Crizanlizumab (crizanlizumab-tmca)AdakveoCD62 (aka P-selectin)Full-length antibodyMonospecificHumanizedhIgG2kappaUnconjugatedNone-Hematological DisordersSickle cell disease20202019US, 2019Chinese hamster ovary (CHO) cells
Concizumab(Pending)Tissue factor pathway inhibitorFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge-stabilizationHemostasisHemophilia A or B NANARegulatory review in JapanTo be confirmed
Cetuximab saratolacanAkalux® IV InfusionEGFRFull-length antibodyMonospecificChimericIgG1kappaPhotoimmunotherapyIRDye® 700DXNone-OncologyHead and neck cancerNANAJapan, 2020To be confirmed
CetuximabErbituxEGFRFull-length antibodyMonospecificChimeric mouse/humanhIgG1kappaUnconjugatedNone-OncologyColorectal cancer20042004Switzerland, 2003Murine myeloma cells (Sp2/0)
Certolizumab pegolCimziaTNFPEGylated FabMonospecificHumanizedhFabPEGylatedPEGextend half lifeNot applicable
-ImmunologyCrohn disease20092008US, 2008E. coli bacteria
Cemiplimab (cemiplimab-rwlc)LibtayoPD-1Full-length antibodyMonospecificHumanhIgG4kappaUnconjugatedS228PHinge stabilisingOncologyCutaneous squamous cell carcinoma20192018US, 2018Chinese hamster ovary (CHO) cells
CatumaxomabRemovabEPCAM, CD3Full-length antibodyBispecificHybrid Rat/MousemIgG2a/k and rIgG2b/λ Hybridkappa/lambdaUnconjugatedNone-OncologyMalignant ascites2009#NAEU, 2009Rat-mouse hybrid-hybridoma cell line
Casirivimab + imdevimabREGEN-COV, RonapreveSARS-CoV-2Full-length antibodies, mixture of 2MonospecificHumanhIgG1kappa and lambdaUnconjugatedNone-Infectious diseasesCOVID-192021In reviewJapan, 2021Chinese hamster ovary (CHO) cells
Caplacizumab (caplacizumab-yhdp)Cablivivon Willebrand factorNanobodyMonospecificHumanizedbivalent NanobodyNAUnconjugatedNot applicable
-ImmunologyAcquired thrombotic thrombocytopenic purpura20182019EU, 2018E. coli bacteria
CanakinumabIlarisIL-1βFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-Genetic DiseasesMuckle-Wells syndrome20092009US, 2009Murine myeloma cells (Sp2/0)
CamrelizumabAiRuiKaPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationOncologyHodgkin's lymphomaNANAChina, 2019To be confirmed
Cadonilimab开坦尼®PD-1, CTLA4Full-length antibodyBispecificHumanizedIgG1kappaUnconjugatedL234A/L235A/G237AReduce Fc effector functionOncologyCervical cancerNANAChina, 2022To be confirmed
Burosumab (burosumab-twza)CrysvitaFGF23Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-Genetic DiseasesX-linked hypophosphatemia20182018EU, 2018Chinese hamster ovary (CHO) cells
Brolucizumab (brolucizumab-dbll)BeovuVEGF-AscFvMonospecificHumanizedhscFvkappaUnconjugatedNot applicable
-OphthalmologyNeovascular age-related macular degeneration20202019US, 2019E. coli BL21(DE3) bacteria
BrodalumabSiliq, LUMICEF, KyntheumIL-17RFull-length antibodyMonospecificHumanhIgG2kappaUnconjugatedNone-ImmunologyPlaque psoriasis20172017Japan, 2016Chinese hamster ovary (CHO) cells
Brentuximab vedotinAdcetrisCD30Full-length antibodyMonospecificChimeric mouse/humanhIgG1kappaADCprotease cleavable linker (Cathepsin cleavable valine-citrulline)Monometyl auristan E (MMAE)tubulin polymerization inhibitorNone-OncologyHodgkin lymphoma, systemic anaplastic large cell lymphoma 20122011US, 2011Chinese hamster ovary (CHO) cells
BlinatumomabBlincytoCD19, CD3Tandem scFvBispecificMurineTandem scFvNAUnconjugatedNot applicable
-OncologyAcute lymphoblastic leukemia20152014US, 2014Chinese hamster ovary (CHO) cells
BimekizumabBimzelxIL-17A and IL-17F (overlapping binding site)Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-ImmunologyPsoriasis2021In reviewEU, 2021Chinese hamster ovary (CHO) cells
BezlotoxumabZinplavaClostridium difficile enterotoxin BFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-Infectious DiseasesPrevention of Clostridium difficile infection recurrence20172016US, 2016Chinese hamster ovary (CHO) cells
BevacizumabAvastinVEGFFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-OncologyColorectal cancer20052004US, 2004Chinese hamster ovary (CHO) cells
BenralizumabFasenraIL-5R αFull-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedAfucosylatedImprove FcγRIIIa binding/Improve ADCCImmunologyAsthma20182017US, 2017Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology)
BelimumabBenlystaBLySFull-length antibodyMonospecificHumanhIgG1lambdaUnconjugatedNone-ImmunologySystemic lupus erythematosus20112011US, 2011Murine myeloma non-secreting 0 (NS0) cells
Belantamab mafodotin (belantamab mafodotin-blmf)BLENREPB-cell maturation antigenFull-length antibodyMonospecificHumanizedhIgG1kappaADCnoncleavable maleimidocaproyl (mc) linkerMonomethyl Auristatin F (MMAF)tubulin polymerization inhibitorAfucosylatedImprove FcγRIIIa binding/Improve ADCCOncologyMultiple myeloma20202020US, 2020Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology)
BasiliximabSimulectIL-2RFull-length antibodyMonospecificChimeric mouse/humanhIgG1kappaUnconjugatedNone-ImmunologyPrevention of kidney transplant rejection19981998US, 1998Murine myeloma non-secreting 0 (NS0) cells
AvelumabBavencioPD-L1Full-length antibodyMonospecificHumanhIgG1lambdaUnconjugatedNone-OncologyMerkel cell carcinoma20172017US, 2017Chinese hamster ovary (CHO) cells
Atoltivimab, maftivimab, and odesivimab-ebgnInmazebEbola virusFull-length antibodies, mixture of 3MonospecificHumanhIgG1kappaUnconjugatedNone-Infectious DiseasesEbola virus infectionNA2020US, 2020Chinese hamster ovary (CHO) cells
AtezolizumabTecentriqPD-L1Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedAglycosylated (N297A)Remove Fc effector functionsOncologyBladder cancer20172016US, 2016Chinese hamster ovary (CHO) cells
Ansuvimab-zyklEbangaEbola virus glycoproteinFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-Infectious DiseasesEbola virus infectionNA2020US, 2020Chinese hamster ovary (CHO) cells
Anifrolumab, anifrolumab-fniaSaphneloIFNAR1Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedL234F; L235E; P331SRemove Fc effector functionsImmunologySystemic lupus erythematosus20222021US, 2021Mouse myeloma cells (NS0)
Amubarvimab + RomlusevimabSARS-CoV-2Full-length antibodyTwo monospecific antibodiesHumanIgG1kappa and lambda2UnconjugatedM252Y/S254T/T256EHalf-life extensionInfectious diseaseSARS-CoV-2 infectionNANAChina, 2021To be confirmed
AmivantamabRYBREVANTEGFR, cMETFull-length antibodyBispecificHumanhIgG1UnconjugatedLow-fucose; K409R; F405LImprove FcγRIIIa binding/Improve ADCC; Controlled Fab arm exchange for bispecific generationOncologyNSCLC w/ EGFR exon 20 insertion mutations20212021US, 2021Chinese hamster ovary (CHO) cells, Low-fucose production cells
AlirocumabPraluentPCSK9Full-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-OtherHigh cholesterol20152015US, 2015Chinese hamster ovary (CHO) cells
AlemtuzumabLemtrada; MabCampath, Campath-1H CD52Full-length antibodyMonospecificHumanizedhIgG1kappaUnconjugatedNone-OncologyMultiple sclerosis; chronic myeloid leukemia#2013; 2001#2014; 2001#US, 2001Chinese hamster ovary (CHO) cells
AducanumabADUHELMAmyloid betaFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-Neurological disordersAlzheimer's diseaseMAA withdrawn2021US, 2021Chinese hamster ovary (CHO) cells
Ado-trastuzumab emtansineKadcylaHER2Full-length antibodyMonospecificHumanizedhIgG1kappaADCNon-cleavable SMCC thioether linkerDM1tubulin polymerization inhibitorNone-OncologyBreast cancer20132012US, 2012Chinese hamster ovary (CHO) cells
Adebrelimab(Pending)PD-L1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228P, F234A, L235A Hinge stabilisation; abrogate effector functionOncologySmall cell lung cancerNANARegulatory review in ChinaTo be confirmed
AdalimumabHumiraTNFFull-length antibodyMonospecificHumanhIgG1kappaUnconjugatedNone-ImmunologyRheumatoid arthritis20032002US, 2002Chinese hamster ovary (CHO) cells
AbciximabReoproGPIIb/IIIaFabMonospecificChimeric mouse/humanhIgG1 FabkappaUnconjugatedNot applicable
-Hematological DisordersPrevention of blood clots in angioplasty1995*1994US, 1994Murine myeloma cells (Sp2/0)
[fam-]trastuzumab deruxtecan, (fam-trastuzumab deruxtecan-nxki)EnhertuHER2Full-length antibodyMonospecificHumanizedhIgG1kappaADCGlycine-Glycine-Phenylalanine-Glycine (GGFG; Cleavable linker)DXdtopoisomerase I inhibitorNone-OncologyHER2+ metastatic breast cancer20212019US, 2019Chinese hamster ovary (CHO) cells
RabiShieldRabies virus G glycoproteinFull-length antibodyMonospecificHumanIgG1UnconjugatedInfectious diseaseRabies exposureNANAIndia, 2016To be confirmed
Cosibelimab(Pending)PD-L1Full-length antibodyMonospecificHumanIgG1lambdaUnconjugatedNoneOncologySquamous cell carcinomaNAIn reviewTo be confirmed

Table notes: *, Country-specific approval. #,  Withdrawn or marketing discontinued. NA, not approved or in review in the EU; not approved or information on review status not available in US.

Sequence and structure information can be accessed on the IMGT/mAb-DB website.

Antibody therapeutics that are approved for marketing in regions other than the EU or US include:
Nimotuzumab (TheraCIM®, BIOMAB-EGFR®), humanized anti-EGFR IgG1 approved in numerous countries for various forms of solid tumors starting in the 2000s.

Itolizumab (Alzumab), humanized anti-CD6 IgG1 approved in India in January 2013 for psoriasis;
Rmab (RabiShield), human anti-rabies virus G glycoprotein IgG1 approved in India in 2016 for post-exposure prophylaxis of rabies;
RabiMabs (Twinrab TM), mixture of 2 anti-rabies virus mAbs approved in India in 2019.

Sintilimab (Tyvyt), human IgG4 anti-PD-1 mAb approved in China in December 2018 for Hodgkin’s lymphoma;
Toripalimab (Tuoyi), humanized anti-PD-1 mAb approved in China in December 2018 for melanoma;
Camrelizumab, humanized anti-PD-1 mAb approved in China in 2019 for Hodgkin’s lymphoma;
Tislelizumab, humanized anti-PD-1 mAb, approved in China in December 2019 as a treatment for classical Hodgkin’s lymphoma;
Disitamab vedotin (Aidixi), anti-HER2 humanized ADC approved in China in June 2021 as a treatment for gastric cancer;
Penpulimab, ant-PD-1 humanized mAb approved in China in August 2021 for Hodgkin’s lymphoma;
Zimberelimab, anti-PD-1 human mAb approved in China in August 2021 for Hodgkin’s lymphoma.

Netakimab (Efleira), anti-IL-17 mAb approved in Russia in 2019 for plaque psoriasis;
Prolgolimab (Forteca), anti-PD-1 mAb approved in Russia in 2020 for melanoma;
Olokizumab (Artlegia), anti-IL-6 humanized IgG4 approved in Russia in 2020 for rheumatoid arthritis;
Levilimab (Ilsira) anti-IL-6R human mAb approved in Russia in 2020 for COVID-19.

Cetuximab saratolacan sodium, anti-EGFR mAb approved in Japan in September 2020 for head and neck cancer;
Pabinafusp alfa (IZCARO), anti-transferrin receptor inmmunoconjuate approve in Japan in March 2021 for Hunter syndrome.

Sotrovimab, anti-SARS-CoV-2 antibody approved in Australia in August 2021.
Regdanvimab, anti-SARS-CoV-2 antibody approved in the Republic of Korea in September 2021.

  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals